An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
How do we assess the needs of people with severe multiple disabilities? Unable to communicate verbally and physically, this population has nearly no possibility of expressing itself. Thanks to ...
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders through chronic inflammation. However, its role in multiple sclerosis, a ...
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...
In a world built around the ideals of productivity, able-bodiedness, and neurotypicality, individuals suffering from mental and physical disabilities often find themselves pushed to the margins- not ...
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid ...
Forbes contributors publish independent expert analyses and insights. Andrew Pulrang writes about disability practices, policy, and culture. Disability activism is empowering. For some disabled people ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results